Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jun 1;26(2):123–131. doi: 10.3904/kjim.2011.26.2.123

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Erythropoietin therapy, hemodialysis (HD) and peritoneal dialysis (PD) therapy characteristics. (A) Changes in hematocrit (%) in patients undergoing dialysis: HD vs. PD. Note the increase in the hematocrit of patients undergoing HD. (B) Percent distribution of erythropoietin (EPO) doses prescribed for patients undergoing HD and PD. (C) Currently using HD membrane and dialysis membrane reuse and percentage of hemodiafiltration (HDF) in private clinics. (D) Distribution of the urea reduction ratio (URR) in patients undergoing HD. Note the difference between males and females. (E) Dialysis adequacy parameters (nPCR and Kt/V) of patients undergoing HD. (F) Dialysis adequacy parameters (Kt/V) for patients with diabetes mellitus (DM) and nonDM who were undergoing HD. (G) Annual changes in dialysis adequacy parameters for patients undergoing HD. (H) Percent distribution of peritoneal dialysis type and doses (2009, n = 2,836). CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis.